Table 1.
Baseline characteristics of participants
| Characteristics | Participants (n = 44) |
|---|---|
| Male sex | 18 (40.9) |
| Age, years | 63.5 [44–73.5] |
| Duration of epilepsy, years | 7.5 [1.5–18.5] |
| Type of seizure | |
| Focal onset | 26 (59.1) |
| Focal to bilateral tonic–clonic | 13 (29.6) |
| Focal onset and focal to bilateral tonic–clonica | 5 (11.3) |
| Aetiology | |
| Structural | 26 (59.1) |
| Metabolic | 1 (2.3) |
| Unknown | 17 (38.6) |
| Any psychiatric comorbidity | 13 (29.5) |
| Number of prior ASMsb | 2 [1–3] |
| Levetiracetam status | |
| Never used | 11 (25.0) |
| Prior use | 33 (75.0) |
| Reason to introduce brivaracetam | |
| Lack of efficacy with other ASMs | 16 (36.4) |
| Adverse events with other ASMs | 21 (47.7) |
| Both | 7 (15.9) |
| Seizure freedom at baseline | 17 (39.0) |
| Baseline monthly seizure frequencyc | 0.5 [0.3–0.8] |
Data are median [IQR] for continuous variables and n (%) for categorical variables
ASM antiseizure medication, BRV brivaracetam, IQR interquartile range
aSubjects presenting both focal onset and focal to bilateral tonic–clonic seizures
bNumber of lifetime ASMs before starting treatment with BRV monotherapy
cBased on the number of seizures during the 6 months before starting BRV monotherapy in non-seizure-free subjects